Poniard Pharmaceuticals is a specialty pharmaceutical company focused on the discovery.

Intravenous chemotherapy, it is designed to overcome and prevent platinum resistance associated with chemotherapy for solid tumors. Picoplatin in clinical trials in clinical trials for the treatment of small cell lung cancer, colon cancer and hormone refractory prostate cancer. As part of of the strategic goal of building a diverse oncology pipeline , the company with the Scripps Research Institute , together on the discovery of novel, small molecule, multi-target protein kinase inhibitors and focal adhesion kinase inhibitors. For more information, please visit.. Poniard Pharmaceuticals is a specialty pharmaceutical company focused on the discovery, development and commercialization of innovative oncology products impact the lives of people with cancer. Picoplatin, the Company’s lead compound is a new generation platinum therapy with an improved safety profile.

Studies of beta – cells of individuals with CHI does not only teach us about the mechanisms of the disease, but may provide clues to the underlying mechanisms of type 1 and type 2 diabetes, as a as a result of loss of function of the beta cells. A team of researchers Jean-Claude Jean-Claude Henquin, at the University of Louvain, Belgium, now has in vitro, pancreatic tissue from patients with CHI and generated data that is not explained by classic models of beta cell function analyzed can be obtained. As in an accompanying commentary by Benjamin Glaser, in mice at the Hadassah-Hebrew University Medical Center, the comprehensive work of Henquin and colleagues represents a milestone in the beta-cell research. Continue reading “Poniard Pharmaceuticals is a specialty pharmaceutical company focused on the discovery.”